Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Mikkael A. Sekeres; Amer M. Zeidan; V. Santini; Rami S. Komrokji; Pierre Fenaux; Michael R. Savona; Yazan F. Madanat; David Valcárcel; Antoine Regnault; Kristin Creel; Libo Sun; Ying Wan; Shyamala Navada; Tymara Berry; Faye Feller; Uwe Platzbecker; María Diez‐Campelo; Esther Natalie Oliva

doi:10.3324/haematol.2025.288956

Key Points

This research aims to evaluate the impact of imetelstat on quality of life and patient-reported outcomes in lower-risk myelodysplastic syndromes.
Phase III IMerge study design was utilized with a focus on RBC transfusion independence.
Assessment of patient-reported outcomes using specific quality of life questionnaires.
Comparison of outcomes between imetelstat and placebo treatment groups.
Imetelstat resulted in significant increases in RBC transfusion independence compared to placebo.
More patients treated with imetelstat reported sustained improvements in fatigue and quality of life.
Fewer patients on imetelstat experienced deterioration in fatigue levels.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Phase III IMerge study shows imetelstat enhances quality of life in patients with lower-risk myelodysplastic syndromes, indicating therapeutic potential.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Sekeres et al. (2026) studied this question.

synapsesocial.com/papers/6974606dbb9d90c67120a4c4 https://doi.org/10.3324/haematol.2025.288956

View Full Paper

Ask AI

Bookmark

Share

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading